Bacillus BoNT Expression for Full-Length Neurotoxin Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing Botulinum neurotoxins (BoNTs) are time-consuming and costly, and Escherichia coli cells struggle to express large proteins like BoNTs, especially engineered or chimeric toxins, hindering large-scale industrial production.
Innovation Solution
Utilizing Bacillus cells, such as Bacillus subtilis, to recombinantly produce BoNTs by culturing them under suitable conditions, incorporating nucleotide sequences encoding BoNTs operably linked to promoters, and using expression vectors with affinity tags, and purifying the BoNTs through chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If E. coli cells are used to express BoNTs, then the production process is simple, but the expression of large proteins like BoNTs is poor and results in truncated products
Solution Approach 1:
The patent replaces E. coli with Bacillus subtilis as a disposable host system that is easier to engineer and scale. While E. coli is traditionally used, Bacillus subtilis provides superior protein folding capabilities and lacks the truncation issue, making it a more reliable but less traditionally used host system.
Solution Approach 2:
The patent changes the host organism parameter from E. coli to Bacillus subtilis, fundamentally altering the cellular environment for protein expression. This parameter change enables proper folding and full-length production of BoNTs while maintaining ease of genetic manipulation and scaling capabilities.
2Reliability
If traditional BoNT production methods are used, then the process is established, but it is time-consuming and costly for large-scale production
Solution Approach 1:
The patent creates a recombinant Bacillus subtilis system that copies the BoNT production capability from C. botulinum without requiring the actual toxin-producing organism. This allows standardized, scalable production in a safer and more efficient host system, improving productivity while maintaining reliability through controlled laboratory conditions.
Solution Approach 2:
The patent performs preliminary genetic engineering to create a stable Bacillus subtilis strain with the BoNT gene integrated into its genome. This preliminary action of creating a standardized recombinant strain enables rapid, consistent, and scalable production, eliminating the need for time-consuming traditional production methods while maintaining reliability.
3Reliability
If BoNTs are produced in C. botulinum, then the native production method is used, but it is unsafe and difficult to control for industrial production
Solution Approach 1:
The patent uses Bacillus subtilis as an intermediary host system to produce BoNTs. This intermediary organism is safe for industrial production, easily manipulated genetically, and capable of producing full-length active BoNTs, thereby mediating between the need for reliable BoNT production and the requirements for safety and manufacturability.
Solution Approach 2:
The patent employs Bacillus subtilis as a disposable, easily discarded host system that can be safely contained and controlled in industrial settings. This intermediary organism can be rapidly produced, used, and disposed of without safety concerns, unlike C. botulinum, while maintaining the ability to produce reliable BoNT quantities.
Data Source
AI summary
Described herein are Bacillus cells comprising a nucleotide sequence encoding a Botulinum neurotoxin (BoNT) and methods of producing the BoNT.